PHASE I DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Sun, Michael
Nauseef, Jones
Fajardo, Andres Ricaurte
Davidson, Zachary
Thomas, Joseph
Ruder, Samuel
Stangl-Kremser, Judith
Castellanos, Sandra Huicochea
Molina, Ana
Sternberg, Cora
Patel, Amie
Yuan, Sarah
Fernandez, Escarleth
Fung, Edward
Avlonitis, Vasilios
O'Dwyer, Elisabeth
Nanus, David
Osborne, Joseph
Bander, Neil
Tagawa, Scott
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
10.1097/01.JU.0001009540.33579.43.11
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD01-11
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [1] Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Osborne, Joseph
    Fernandez, Escarleth
    Thomas, Charlene
    Niaz, Muhammad Junaid
    Ciriaco, Amy
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Babich, John
    Nanus, David M.
    Ballman, Karla, V
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
    Sun, Michael
    Nauseef, Jones T.
    Lebenthal, Justin M.
    Niaz, Muhammad Junaid
    Singh, Sharon
    Chamberlain, Tessa A.
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Vallabhajosula, Shankar
    Babich, John
    Christos, Paul J.
    Osborne, Joseph
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Jhanwar, Yuliya
    Ballman, Karla V.
    Hackett, Amy
    Emmerich, Lauren
    Babich, John
    Sartor, A. Oliver
    Harshman, Lauren Christine
    Beltran, Himisha
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Osborne, Joseph
    Niaz, Muhammad Junaid
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Thomas, Charlene
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Fernandez, Escarleth
    Babich, John
    Nanus, David M.
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer
    Nauseef, Jones T.
    Sun, Michael
    Thomas, Charlene
    Bissassar, Mahelia
    Fernandez, Escarleth
    Davidson, Zachary
    Patel, Amie
    Tan, Angela
    Chamberlain, Tessa A.
    Earle, Kara
    Wunder, Rebecca
    Guervil, Sabrina
    Castellanos, Sandra H.
    Stangl-Kremser, Judith
    Gregos, Peter S.
    Osborne, Joseph R.
    Ballman, Karla V.
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil H.
    Tagawa, Scott T.
    CANCER RESEARCH, 2023, 83 (08)
  • [6] A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.
    Nauseef, Jones T.
    Sun, Michael Philip
    Thomas, Charlene
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Fernandez, Escarleth
    Davidson, Zachary
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Castellanos, Sandra Huicochea
    Gregos, Peter
    Osborne, Joseph
    Ballman, Karla V.
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] PSMA-targeted alpha radioimmunotherapy for prostate cancer with 225Ac-J591
    Batra, Jaspreet S.
    Liu, He
    Kim, Sae
    Navarro, Vicente N.
    Vallabhajosula, Shankar
    Tagawa, Scott T.
    Bander, Neil H.
    CANCER RESEARCH, 2017, 77
  • [8] Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Sun, Michael
    Sartor, A. Oliver
    Thomas, Charlene
    Singh, Sharon
    Bissassar, Mahelia
    Fernandez, Escarleth
    Niaz, Muhammad Junaid
    Ho, Benedict
    Vallabhajosula, Shankar
    Babich, John
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591
    Tagawa, Scott T.
    Thomas, Charlene
    Sartor, A. Oliver
    Sun, Michael
    Stangl-Kremser, Judith
    Bissassar, Mahelia
    Vallabhajosula, Shankar
    Castellanos, Sandra Huicochea
    Nauseef, Jones T.
    Sternberg, Cora N.
    Molina, Ana
    Ballman, Karla
    Nanus, David M.
    Osborne, Joseph R.
    Bander, Neil H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (07) : 842 - 851
  • [10] Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Batra, Jaspreet
    Christos, Paulj.
    Jhanwar, Yuliya
    Goldsmith, Stanley J.
    Nanus, David M.
    Beltran, Himisha
    Molina, Ana M.
    Faltas, Bishoy
    Hackett, Amy
    Sreekumar, Jyothi
    Babich, John
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345